CLDX · Celldex Therapeutics, Inc.
Is CLDX setting up for a breakout, what are traders on X and the news saying, are its insiders buying, and how is the business doing? Everything Raspberry Trades measures on Celldex Therapeutics, Inc., in one place.
Today's breakout radarIs CLDX setting up for a breakout?
Breakout Radar API →Not today. CLDX is not on today's radar: no tight base just under a resistance that has been tested again and again.
See the stocks that are setting up today →What are traders on X saying about CLDX?
Stock Sentiment API →Bulls: Posts flag the CSU indication as larger than initially assumed, framing it as an underappreciated opportunity for $CLDX alongside $REGN and $SNY. A hedge-fund screen shows $CLDX held by 10 of 36 biopharma-focused funds, the highest count among the tickers listed ($HELP 8/36, $ZURA 6/36, $RZLT 4/36).
Bears: $CLDX closed Monday at $29.50, below both its 50-day SMA ($34.97) and 200-day SMA ($32.34), sitting in the lower part of its 20-day range of $27.47–$32.88. Daily RSI stood at 42, reflecting weak momentum.
Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.
What is the news saying about CLDX?
News Sentiment API →No recent news reading for CLDX. The News Sentiment API reads today's headlines on any US stock.
Are CLDX insiders buying or selling?
Insider Trading API →Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.
- Sold · Jimenez Freddy A.$121K · Dec 4, 2025
- Sold · Wright Richard M.$1.2M · Nov 13, 2025
- Sold · Jimenez Freddy A.$11K · Aug 13, 2025
- Sold · Jimenez Freddy A.$8K · Aug 13, 2025
How is Celldex Therapeutics, Inc.'s business doing?
Financial Statements API →| Quarter ended | Revenue | vs year before | Net income | EPS |
|---|---|---|---|---|
| Jun 30, 2026 | $22K | -97% | −$73.5M | $-0.94 |
| Mar 31, 2026 | $15K | -98% | −$78.7M | $-1.18 |
| Sep 30, 2025 | $0 | -100% | −$67.0M | $-1.01 |
| Jun 30, 2025 | $730K | -71% | −$56.6M | $-0.85 |
From the company's SEC filings (10-Q and 10-K).
What does Celldex Therapeutics, Inc. expect?
Company Guidance API →- through 2028 · cash runway · 8-K filed Aug 6, 2026
“Celldex believes that the cash, cash equivalents and marketable securities at June 30, 2026 are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.”
- through 2028 · cash runway · 8-K filed May 7, 2026
“Celldex believes that the cash, cash equivalents and marketable securities at March 31, 2026, along with the approximately $323.9 million in net proceeds from our April 2026 underwritten public offering, are sufficient to meet estimated working capital requirements and fund current planned operations through 2028.”
- through 2027 · cash runway · 8-K filed Feb 25, 2026
“Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2025 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.”
- through 2027 · cash runway · 8-K filed Nov 10, 2025
“Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2025 are sufficient to meet estimated working capital requirements and fund current planned operations through 2027.”
Quoted from the outlook the company filed with the SEC.
Free account, no card: today's top 5 with charts, by email before the open.
Measured data, not recommendations. Not investment advice.